康艾注射液联合盐酸埃克替尼片治疗晚期非小细胞肺癌的疗效观察

Efficacy of Kang Ai Injection combined with icotinib hydrochloride tablets in the treatment of advanced non-small cell lung cancer

目的探讨康艾注射液联合盐酸埃克替尼片治疗晚期非小细胞肺癌的临床疗效。方法选取2013年5月—2018年5月在洛阳市第三人民医院就诊的82例晚期非小细胞肺癌患者,随机分为观察组(n=41)和对照组(n=41)。对照组给予患者口服盐酸埃克替尼片,3次/d,125 mg/次。观察组在对照组基础上给予康艾注射液40 mL,1次/d。两组均治疗1个月。对比两组治疗效果、生活质量和毒副作用发生率。结果与对照组治疗总有效率12.20%和病情控制率48.78%比较,观察组治疗总有效率31.71%和病情控制率85.37%均显著升高(P<0.05)。两组呼吸困难、便秘、食欲缺乏发生率,角色功能、认知功能、社会功能评分及毒副作用(肝功能异常和腹泻)发生率比较,差异均无统计学意义。观察组疲倦、疼痛和皮疹发生率均显著低于对照组(P<0.05);躯体功能、情绪功能评分均显著高于对照组(P<0.05)。结论康艾注射液联合盐酸埃克替尼片治疗晚期非小细胞肺癌疗效显著,且安全性良好,值得临床推广。

Objective To investigate the clinical efficacy of Kang Ai Injection combined with Icotinib Hydrochloride Tablets in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 82 patients with advanced NSCLC from May 2013 to May2018 were randomly divided into observation group(icotinib hydrochloride+Kang Ai Injection,n=41)and control group(icotinib hydrochloride,n=41).The therapeutic effect,quality of life and incidence of side effects were compared between the two groups.Results The total effective rate 31.71%and disease control rate 85.37%in the observation group were significantly higher than those in the control group(12.20%&48.78%)(P<0.05).There was no significant difference in the incidence of dyspnea,constipation,anorexia,role function,cognitive function and social function score,incidence of toxic side effects(abnormal liver function and diarrhea)between the two groups.The incidence of fatigue,pain and rash in the observation group were significantly lower than those in the control group(P<0.05),and the scores of physical function and emotional function were significantly higher than those in the control group(P<0.05).Conclusion Kang Ai Injection combined with Icotinib Hydrochloride Tablets is effective and safe in the treatment of advanced NSCLC.